Insulet (NASDAQ:PODD – Get Free Report) had its price target boosted by equities researchers at Citigroup from $310.00 to $355.00 in a note issued to investors on Friday,Benzinga reports. The ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...

Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...

CIBC Asset Management Inc increased its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 4.7% in the 4th ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

In today's episode of Yeh Rishta Kya Kehlata Hai, Abhira and Armaan argue with Abhir and Kiara for making the wrong decision.

Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...